Gabriele Madonna

List of Publications by Year
in descending order

54	1,741	394421 19	361022 35
papers	citations	h-index	g-index

56	56	56	3607
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. , 2018, 6, 74.		292
2	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Research, 2019, 29, 846-861.	12.0	160
3	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research, 2016, 22, 4848-4858.	7.0	146
4	NF-κB as potential target in the treatment of melanoma. Journal of Translational Medicine, 2012, 10, 53.	4.4	118
5	miR-579-3p controls melanoma progression and resistance to target therapy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5005-13.	7.1	99
6	Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma. OncoImmunology, 2018, 7, e1387706.	4.6	76
7	Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. Journal of Translational Medicine, 2017, 15, 244.	4.4	73
8	Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. OncoImmunology, 2015, 4, e1008842.	4.6	72
9	MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAFV600E Mutation Detected in Circulating-Free DNA. Frontiers in Pharmacology, 2018, 9, 856.	3.5	68
10	IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. OncoImmunology, 2017, 6, e1261242.	4.6	59
11	Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway. Cancer Immunology Research, 2019, 7, 841-852.	3.4	47
12	PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. OncoImmunology, 2018, 7, e1405206.	4.6	43
13	Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma. Scientific Reports, 2019, 9, 7449.	3.3	43
14	Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations. BMC Cancer, 2013, 13, 17.	2.6	38
15	First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. Cancer Immunology, Immunotherapy, 2019, 68, 765-772.	4.2	35
16	Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents. , 2022, 10, e004043.		34
17	Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy. , 2020, 8, e001689.		33
18	Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients. Journal of Translational Medicine, 2020, 18, 121.	4.4	29

#	Article	IF	Citations
19	Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma. Oncotarget, 2018, 9, 18997-19005.	1.8	25
20	Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations. , 2019, 7, 91.		24
21	CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. European Journal of Cancer, 2018, 97, 59-61.	2.8	22
22	ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin. Cancers, 2019, 11, 1425.	3.7	22
23	No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. Cancers, 2021, 13, 475.	3.7	20
24	Integrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in Melanoma. International Journal of Molecular Sciences, 2021, 22, 1801.	4.1	20
25	MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab. Journal of Translational Medicine, 2014, 12, P11.	4.4	12
26	Melanoma and immunotherapy bridge 2015. Journal of Translational Medicine, 2016, 14, 65.	4.4	12
27	A Psychosocial Genomics Pilot Study in Oncology for Verifying Clinical, Inflammatory and Psychological Effects of Mind-Body Transformations-Therapy (MBT-T) in Breast Cancer Patients: Preliminary Results. Journal of Clinical Medicine, 2021, 10, 136.	2.4	12
28	Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. Journal of Translational Medicine, 2022, 20, 159.	4.4	12
29	Immunoscore: a new possible approach for melanoma classification. , 2014, 2, .		9
30	Translational significance of Nodal, Cripto-1 and Notch4 in adult nevi. Oncology Letters, 2016, 12, 1349-1354.	1.8	9
31	The Ratio of GrzB+ ẫ FoxP3+ over CD3+ T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma. Cancers, 2021, 13, 2325.	3.7	7
32	A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. Journal of Translational Medicine, 2021, 19, 17.	4.4	6
33	Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors. Frontiers in Immunology, 2022, 13, 811131.	4.8	6
34	Bleeding in Plasticâ€"Aesthetic Surgery: A Prognostic Pathway with Clinical Application. Aesthetic Plastic Surgery, 2020, 44, 201-206.	0.9	5
35	Ipilimumab and Stereotactic Radiosurgery with CyberKnifeÂ® System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience. Cancers, 2021, 13, 1857.	3.7	5
36	Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy. Cancers, 2021, 13, 4164.	3.7	5

#	Article	IF	Citations
37	Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients. Scientific Reports, 2022, 12, 5448.	3.3	5
38	Clinical Outcome Prediction in COVID-19 Patients by Lymphocyte Subsets Analysis and Monocytes' iTNF-Î± Expression. Biology, 2021, 10, 735.	2.8	4
39	Enzyme activity of circulating CD73 in human serum. Methods in Enzymology, 2019, 629, 257-267.	1.0	3
40	Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave. Journal of Translational Medicine, 2021, 19, 93.	4.4	3
41	Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma. Journal of Translational Medicine, 2015, 13, .	4.4	2
42	Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients. Journal of Translational Medicine, 2015, 13, O8.	4.4	2
43	Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts. Journal of Translational Medicine, 2018, 16, .	4.4	2
44	Multiplex immunohistochemistry assay to evaluate the melanoma tumor microenvironment. Methods in Enzymology, 2020, 635, 21-31.	1.0	2
45	Abstract 558: Prognostic gene signature use in checkpoint inhibitor monotherapy for melanoma. , 2018, , .		2
46	Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for clinical response biomarker identification. , 2013, 1, .		1
47	Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification. Journal of Translational Medicine, 2014, 12, O13.	4.4	1
48	Immunoscore as new possible approach for the classification of melanoma.. Journal of Clinical Oncology, 2014, 32, e20020-e20020.	1.6	1
49	Bleeding in Plastic-Aesthetic Surgery: A Prognostic Pathway with Clinical Application. Aesthetic Plastic Surgery, 2020, 44, 1897-1897.	0.9	0
50	Proteomics meets transcriptomics: Identification of tumor tissue signatures specific to anti-PD1 treatment in late-stage melanoma patients.. Journal of Clinical Oncology, 2021, 39, e21543-e21543.	1.6	0
51	Dermatologic adverse events associated with targeted therapies for melanoma. Expert Opinion on Drug Safety, 2022, 21, 385-395.	2.4	0
52	The ACC melanoma pilot project: â€œReal-worldâ€•evaluation of an NGS platform for molecular characterization of melanoma in Italy.. Journal of Clinical Oncology, 2019, 37, e14600-e14600.	1.6	0
53	761â€¦Potential predictive biomarkers of rapid progression and response to anti-PD1 treatment by gene profiling analysis in metastatic melanoma patients. , 2020, , .		0
54	229â€¦Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy. , 2020, , .		0